Kymera Therapeutics, Inc.
KYMRDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 10, 2026
12dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
KYMR Earnings Report
EPS Est: $-0.64 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How KYMR's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KT-621 | Phase 2 | Atopic Dermatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kymera Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Kymera Therapeutics, Inc.'s (KYMR) pipeline across Phase 2. Its lead program is KT-621 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kymera Therapeutics, Inc.'s next FDA catalyst?→
Kymera Therapeutics, Inc.'s (KYMR) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KYMR biotech catalysts?→
Add KYMR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kymera Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.